Aethlon Medical secures patents for Hemopurifier use in Long COVID and CAC treatments, protecting applications through 2042.

Aethlon Medical has secured patents for the use of its Hemopurifier in Long COVID and COVID-19-associated coagulopathy (CAC) treatments. The U.S. patent will issue on September 9, 2025, while the European patent was granted on July 9, 2025. The patents protect Hemopurifier applications in patients with reduced viral loads and persistent Long COVID symptoms, as well as those with CAC who no longer have detectable viral particles. CEO James Frakes noted that the patents strengthen the company's intellectual property in addressing unmet medical needs.

San Diego, CA — Aethlon Medical, Inc. (Nasdaq: AEMD) has announced the issuance of patents for the use of its Hemopurifier® in the treatment of Long COVID and COVID-19-associated coagulopathy (CAC). The U.S. patent, numbered 12,409,260, is set to issue on September 9, 2025, while the European patent, numbered 4136453, was granted on July 9, 2025.

The patents protect the use of the Hemopurifier® in the United States to treat patients who have a reduced COVID-19 viral load but exhibit Long COVID symptoms for more than 12 weeks post-infection. Additionally, the patents cover the treatment of patients experiencing Long COVID symptoms by removing circulating COVID-19 spike protein. For patients with COVID-19-associated coagulopathy (CAC) who no longer have detectable viral particles, the patents protect the use of the Hemopurifier® to treat these conditions.

James Frakes, CEO and CFO of Aethlon, stated, "Securing these patents expands and strengthens our intellectual property portfolio in areas of significant unmet medical need. While the Hemopurifier® remains in the research and development stage relating to Long COVID, these protections position us well as we continue advancing potential future applications. Our goal is to build a strong foundation of innovation that could one day translate into meaningful treatment options for patients."

The Hemopurifier® is an investigational medical device designed to remove enveloped viruses, fragments of viruses, and tumor-derived extracellular vesicles (EVs) from circulation. It is used extracorporeally with a blood pump and combines plasma separation, size exclusion, and affinity binding using a plant lectin resin that targets mannose-rich surfaces found on EVs and viral proteins. The device has demonstrated effectiveness in both in vitro studies and human patients.

Aethlon Medical is a clinical-stage medical device company headquartered in San Diego, California, focusing on addressing unmet needs in oncology and infectious disease. The company is advancing the Hemopurifier® to selectively remove circulation pathogenic targets from biologic fluids.

The patents are significant for Aethlon Medical, as they provide intellectual property protections for the Hemopurifier® in critical areas of medical need. The patents are expected to expire in 2042 (U.S. patent) and 2041 (European patent).

References:
[1] https://www.prnewswire.com/news-releases/aethlon-medical-announces-issuance-of-hemopurifier-patents-for-the-treatment-of-long-covid-and-covid-19-associated-coagulopathy-cac-302544201.html
[2] https://www.marketscreener.com/news/aethlon-medical-announces-issuance-of-hemopurifier-patents-for-the-treatment-of-long-covid-and-covi-ce7d59dbd981f325